Table 2. Anticancer Screenings of the Synthesized Compounds against Caco-2, HCT116, HeLa, and MCF7 Human Cancer Cell Lines^a.

compound no	Caco-2	HCT-116	HeLa	MCF-7
7	165.33 ± 2.45	>200	124.67 ± 4.67	93.43 ± 3.56
8	168.71 ± 1.98	>200	120.98 ± 4.84	98.26 ± 4.41
16	79.67 ± 1.67	91.19 ± 4.23	39.75 ± 2.14	34.79 ± 1.73
17	16.36 ± 1.12	43.45 ± 2.34	4.41 ± 0.23	0.31 ± 0.01
18	19.09 ± 1.02	55.60 ± 2.78	24.65 ± 1.87	17.29 ± 1.13
19	85.72 ± 2.12	97.23 ± 3.45	42.17 ± 2.46	36.06 ± 2.05
20	96.79 ± 3.18	124.32 ± 4.45	56.35 ± 3.78	52.75 ± 3.46
21	99.47 ± 3.15	126.87 ± 4.67	61.10 ± 3.90	54.68 ± 3.57
22	4.98 ± 0.15	19.89 ± 0.63	7.47 ± 0.39	3.31 ± 0.03
23	12.34 ± 1.41	35.78 ± 1.98	29.25 ± 1.23	23.09 ± 1.84
24	10.21 ± 0.38	30.09 ± 1.65	19.05 ± 0.45	14.78 ± 1.23
25	7.22 ± 0.26	22.34 ± 0.87	11.05 ± 0.56	4.46 ± 0.02
26	14.18 ± 1.51	39.55 ± 2.11	31.79 ± 2.04	28.46 ± 1.93
27	11.67 ± 1.34	32.41 ± 1.92	22.08 ± 1.29	18.14 ± 1.14
doxorubicin	5.17 ± 0.25	5.64 ± 0.17	1.25 ± 0.02	0.65 ± 0.01

^aIC₅₀ values are expressed as mean ± SD of three independent experiments.